Senegal: The impact of a study on misoprostol use and knowledge among pharmacists

Eva Burke, Emma C. Robinson, Nafissatou Diop, Kate Reiss, Katharine Footman, Maaike Min, Barbara Reichwein, Ian Askew2016 · DOI

Abstract

The availability of misoprostol is a key part of improving maternal health in low- and middle-income countries. In Senegal, where the drug is not widely available, pharmacies are one of the few places women can access it. STEP UP conducted a study to understand misoprostol knowledge and provision in these pharmacies. The Ministry of Health’s (MoH) commitment to training public providers and pharmacists on all products on the essential medicines list is a promising step toward bettering the health of women in Senegal. Marie Stopes International (MSI) Senegal continues to work to build the capacity of healthcare providers in the public sector, while both MSI Senegal and the Population Council remain committed to supporting the MoH to reduce levels of maternal mortality from postpartum hemorrhage and postabortion care.

Introduction

Maternal mortality remains a critical challenge in Senegal, with 392 deaths per 100,000 live births recorded in 2010/11. Misoprostol is a World Health Organization (WHO) essential medicine for managing postpartum hemorrhage (PPH) and post-abortion care (PAC), yet it is scarcely available in the country.

The authors identify a "utilization gap": while the clinical benefits of misoprostol are well-documented, operational research often fails to translate into policy. In Senegal, misoprostol was largely confined to the private sector and required a prescription, but pharmacists were hesitant to stock or sell it. This paper investigates the specific barriers—whether regulatory, social, or educational—preventing this life-saving drug from reaching the women who need it.

Methods

The STEP UP research consortium. Senegal: The impact of a study on misoprostol use and knowledge among pharmacists, page 3

The STEP UP research consortium.

The project employed Operations Research focused on a Knowledge, Attitudes, and Practices (KAP) framework. In 2013, Marie Stopes International (MSI) and the Population Council surveyed 110 private sector pharmacists in Dakar.

The novelty of this approach lies in the Evidence-to-Impact strategy. The researchers didn't just publish a paper; they used the data to drive change through several key channels:

  1. Re-training "Detailers": Pharmaceutical sales representatives were repurposed as clinical educators to clarify the legal status and correct dosage of misoprostol to pharmacists.
  2. Stakeholder Engagement: They co-hosted dissemination events with the Directorate of Reproductive Health and Child Survival (DSRSE) to ensure the Ministry of Health (MoH) felt "ownership" of the findings.
  3. Institutional Partnership: They collaborated with the "Order of Pharmacists" to build trust and legitimacy before data collection even began.

Key Insights and Ideas

The study revealed several critical barriers to access:

  • The "Abortifacient" Stigma: A significant 42% of pharmacists who didn't stock the drug cited a desire to avoid selling "abortifacient products." This highlighted a massive communication gap: pharmacists were conflating life-saving PPH treatment with elective abortion, leading to self-censorship.
  • The Prescription Bottleneck: Pharmacists reported low sales because they weren't receiving prescriptions. This led to a strategic pivot: MSI realized they couldn't just train pharmacists; they had to train the doctors, nurses, and midwives who write the prescriptions.
  • Knowledge vs. Confidence: While 38% knew misoprostol could induce abortion, only 0.5% knew the correct dosage for PAC. This "dangerous half-knowledge" contributed to a lack of confidence (51% felt unconfident providing the drug), which was a greater barrier than simple lack of supply.
  • The Power of Co-hosting: By co-hosting dissemination events with government bodies (DSRSE), the researchers moved the findings from "external critique" to "internal roadmap."

Key Results

Misoclear on a pharmacy shelf in Senegal. Senegal: The impact of a study on misoprostol use and knowledge among pharmacists, page 3

Misoclear on a pharmacy shelf in Senegal.

The impact of the study and subsequent interventions was rapid and measurable:

  • Increased Availability: The number of pharmacies stocking Misoclear rose from 253 in December 2014 to 415 in June 2015—a 64% increase in just six months.
  • Provider Training: 1,020 public sector providers were trained by January 2015, with plans for an additional 1,200.
  • Policy Shift: The Senegalese Ministry of Health made a formal commitment to train pharmacists on all essential medicines, specifically including misoprostol.
  • Regional Scaling: The success of this "Senegal model" (training both providers and pharmacists) was adopted as MSI’s regional strategy for West Africa.

Limitations and Future Work

The initial KAP study was limited to Dakar; rural access remains a different challenge involving different supply chain hurdles. Furthermore, the impact data on stocking only tracked MSI’s brand, Misoclear, and does not account for other brands of misoprostol that might be on the market. At the time of the report, the MoH's commitment to pharmacist training had not yet been fully implemented. Future research should investigate the specific prescribing habits of clinicians to understand why the "prescription bottleneck" persists even after training.

Summary updated

Abstract

The availability of misoprostol is a key part of improving maternal health in low- and middle-income countries. In Senegal, where the drug is not widely available, pharmacies are one of the few places women can access it. STEP UP conducted a study to understand misoprostol knowledge and provision in these pharmacies. The Ministry of Health’s (MoH) commitment to training public providers and pharmacists on all products on the essential medicines list is a promising step toward bettering the health of women in Senegal. Marie Stopes International (MSI) Senegal continues to work to build the capacity of healthcare providers in the public sector, while both MSI Senegal and the Population Council remain committed to supporting the MoH to reduce levels of maternal mortality from postpartum hemorrhage and postabortion care.
BibTeX
@misc{burke2016senegal,
  author = {Eva Burke and Emma C. Robinson and Nafissatou Diop and Kate Reiss and Katharine Footman and Maaike Min and Barbara Reichwein and Ian Askew},
  title = {{Senegal: The impact of a study on misoprostol use and knowledge among pharmacists}},
  year = {2016},
  doi = {10.31899/rh4.1029},
}
Figure